Turmeric Acquisition Corp.
TMPM
NASDAQ Capital Market10.03
USD
-0.01
- -
CIK
0001823524
ISIN
KYG9127T1085
Return %
Stock
S&P500
1Y
2.24
18.21
3Y
0.30
63.29
5Y
0.30
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 450 Kendall Street Cambridge MA United States of America 02142
- IPO Date
- Dec 16, 2020
- CIK
- 0001823524
- Website
- mpmcapital.com
- Similar Companies
- Business
- Turmeric Acquisition Corp. (TMPM) is a blank check company whose principal business activity is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company focuses on life sciences targets, particularly off-the-radar biotechnology firms developing promising drug candidates in oncology and rare diseases; it offers no operational products or services beyond this acquisition vehicle structure. Founded in 2020 and headquartered at 450 Kendall Street, Cambridge, Massachusetts, Turmeric operates in the United States and was sponsored by MPM Capital, with leadership including CEO Luke Evnin, a co-founder and managing director of MPM Capital, and Chairman Matthew Roden, an executive partner at the firm. In October 2022, the company announced the redemption of all its outstanding Class A ordinary shares and liquidation of its trust account at approximately $10.05 per share after failing to complete an initial business combination within the required timeframe, with shares ceasing trading on October 20, 2022; its warrants also ceased trading, and operations wound down except for dissolution activities. Despite the 2022 liquidation, public market data as of late 2025 shows residual trading activity for Class A shares with a market capitalization around $98 million, zero sales or revenue, and net income of $2.65 million annually, alongside 71% institutional ownership, indicating a post-liquidation shell or data persistence for the entity.
Turmeric Acquisition Corp. Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination
Stemming from SEC Guidance Concerning Balance Sheet Treatment of Warrants, Turmeric Acquisition Corp. Announces Receipt of NASDAQ Continued Listing Standard Notice
Turmeric Acquisition Corp. Announces Pricing of $85 Million Initial Public Offering